OncoMatch/Clinical Trials/NCT05826535
Study of LYL314 in Aggressive Large B-Cell Lymphoma
Is NCT05826535 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including LYL314 and Fludarabine for relapsed non-hodgkin lymphoma.
Treatment: LYL314 · Fludarabine · Cyclophosphamide — This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of LYL314, a dual-targeting chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in participants with aggressive large B-cell lymphoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: anti-CD20 monoclonal antibody
Prior therapy must have included: Anti-CD20 monoclonal antibody
Must have received: anthracycline
Prior therapy must have included: An anthracycline containing chemotherapy regimen
Cannot have received: allogeneic stem cell transplantation
History of allogeneic stem cell or solid organ transplantation
Cannot have received: autologous stem cell transplantation
Exception: within 6 weeks prior to enrollment/leukapheresis
Receipt of autologous stem cell transplantation within 6 weeks prior to enrollment/leukapheresis
Cannot have received: genetically modified cell therapy
Exception: CD19 with an FMC63-based CAR (e.g., axi-cel, tisa-cel, liso-cel) allowed
History of prior genetically modified cell therapy other than a product targeting CD19 with an FMC63-based CAR (e.g., axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tisa-cel), or lisocabtagene maraleucel (liso-cel). For all other CAR T cell therapy treatments, discussion with the Sponsor's Medical Monitor is required
Lab requirements
Blood counts
ANC ≥ 1000/uL; Platelet count ≥ 50,000/uL; Absolute lymphocyte count (ALC) ≥ 200/uL
Absolute neutrophil count (ANC) ≥ 1000/uL; Platelet count ≥ 50,000/uL; Absolute lymphocyte count (ALC) ≥ 200/uL
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California-Irvine Medical Center · Irvine, California
- Cedars-Sinai Medical Center · Los Angeles, California
- University of California, Los Angeles (UCLA) Medical Center · Los Angeles, California
- Scripps Clinic · San Diego, California
- Colorado Blood Cancer Institute · Denver, Colorado
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05826535 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior allogeneic stem cell transplantation, autologous stem cell transplantation, genetically modified cell therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify